Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series of high-profile market withdrawals, the obesity drug landscape has seen several new treatment options launch since 2012, However, uptake of these novel agents has been slow, suggesting suboptimal risk-benefit profiles and reflecting the poor reimbursement environment for prescription weight-loss agents. In this report, endocrinologists reveal how the current antiobesity drugs compare and which attributes the next generation should have to serve this medically important population and succeed commercially in this potentially lucrative market.

Questions Answered

  • How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Saxenda and Currax Pharmaceutical’s Qsymia?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and prices are needed from new obesity drugs to be preferred by endocrinologists?
  • How do less frequent dosing, route of administration, CV and renal benefit, and efficacy influence physician preference?

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S endocrinologists and 30 European endocrinologists fielded in April 2020.

Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Xenical.

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics.

Table of contents

  • Obesity/Overweight - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Executive Summary
      • Unmet Need - Obesity - Executive Summary - June 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Obesity and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Endocrinologists' Prescribing Decisions in Obesity
        • Importance of Efficacy Attributes to Prescribing Decisions in Obesity: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Obesity: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Obesity: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Obesity: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Obesity: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Obesity: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Obesity: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Obesity: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Obesity: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Obesity: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Obesity: United States
        • Overall Performance of Key Therapies for Obesity: Europe
        • Mean Overall Performance of Key Therapies for Obesity: United States and Europe
        • Relative Performance of Key Therapies for Obesity Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Obesity Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Obesity Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Obesity Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Obesity Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Obesity Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Obesity Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Obesity Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Obesity
        • Surveyed Endocrinologists’ Satisfaction with the Performance of Key Therapies for Obesity on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Endocrinologists’ Satisfaction with the Performance of Key Therapies for Obesity on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Obesity: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Obesity: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Obesity: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Obesity: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Obesity: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Obesity: Europe
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Obesity: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Obesity: Europe
        • Key Findings: Unmet Need in Obesity and Related Indications
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need in Obesity and Related Indications: United States
        • Surveyed Endocrinologists' Ascribed Level of Unmet Need in Obesity and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Obesity Market and Emerging Therapy Insights
          • Opportunity: Antiobesity Agents with Greater Sustained Weight Loss
          • Opportunity: An Antiobesity Agent with Robust CV Outcomes Data
          • Opportunity: An Agent Effective in Reducing Adiposity and Preventing Adiposopathy
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
        • Attribute Importance and Part-Worth Utilities
          • Obesity Target Product Profile: Attribute Importance
          • Mean Body Weight Loss After 1 Year
          • Mean Reduction in Body Fat After 1 Year
          • Mean Reduction in HbA1c After 1 Year (in Diabetics)
          • Mean Reduction in Cardiovascular Adverse Event Rates
          • Risk of Neuropsychiatric Adverse Events
          • Dosing Burden
          • Price per Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Obesity Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Obesity Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Obesity Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)

    Rameshwar Prajapati, Ph.D., M.S. (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications.
    Rameshwar holds a bachelor’s degree in pharmacy from Dr. H.S. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.


    Related Reports

    Obesity/Overweight - Landscape & Forecast - Disease Landscape & Forecast

    Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily incre...

    View Details

    Obesity/Overweight - Current Treatment - Obesity | Treatment Algorithms: Claims Data Analysis | US | Dashboard

    Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

    View Details

    Obesity/Overweight - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis -2020

    Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

    View Details

    Obesity/Overweight | Unmet Need | US/EU | 2019

    Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabetes and adverse cardiovascular health. Current t...

    View Details